YTHDF2 and hepatocellular carcinoma: As mentioned before, YTHDF2 is heavily O-GlcNAcylated, and its levels correlate with worse HBV-HCC patient survival, implicating O-GlcNAcylated YTHDF2 as a potential biomarker of aggressive disease.